Ibudilast 20mg + Ibudilast 50mg + Placebo oral tablet
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Methamphetamine-dependence
Conditions
Methamphetamine-dependence, Substance Abuse
Trial Timeline
Jan 1, 2011 → Mar 1, 2013
NCT ID
NCT01217970About Ibudilast 20mg + Ibudilast 50mg + Placebo oral tablet
Ibudilast 20mg + Ibudilast 50mg + Placebo oral tablet is a phase 1 stage product being developed by MediciNova for Methamphetamine-dependence. The current trial status is completed. This product is registered under clinical trial identifier NCT01217970. Target conditions include Methamphetamine-dependence, Substance Abuse.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01217970 | Phase 1 | Completed |